ArticleScientific reports2023

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.

Hang Ke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.